CONMED (CNMD) Set to Announce Quarterly Earnings on Wednesday

CONMED (NYSE:CNMD) is expected to announce its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect CONMED to announce earnings of $1.00 per share and revenue of $336.28 million for the quarter. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

CONMED (NYSE:CNMD) last issued its earnings results on Wednesday, July 29th. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.27. The business had revenue of $343.49 million for the quarter, compared to analyst estimates of $337.60 million. CONMED had a return on equity of 14.31% and a net margin of 4.12%. The business’s quarterly revenue was up .3% on a year-over-year basis. During the same quarter last year, the company earned $1.15 EPS. On average, analysts expect CONMED to post $4.54 EPS for the current fiscal year and $4.73 EPS for the next fiscal year.

CONMED Stock Up 3.3%

Shares of NYSE:CNMD opened at $47.58 on Wednesday. The company has a market capitalization of $1.43 billion, a PE ratio of 25.72, a P/E/G ratio of 2.10 and a beta of 0.94. The company has a current ratio of 1.48, a quick ratio of 0.69 and a debt-to-equity ratio of 0.63. CONMED has a twelve month low of $31.44 and a twelve month high of $53.66. The firm has a 50 day simple moving average of $47.54 and a 200-day simple moving average of $41.44.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Wells Fargo & Company upped their price target on CONMED from $39.00 to $46.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Piper Sandler reiterated a “neutral” rating and issued a $45.00 price objective (up from $39.00) on shares of CONMED in a research report on Thursday, July 30th. Zacks Research upgraded shares of CONMED from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Needham & Company LLC reissued a “hold” rating on shares of CONMED in a research note on Monday, July 13th. Finally, Bank of America restated an “underperform” rating and set a $40.00 price objective on shares of CONMED in a research report on Monday, June 29th. Six research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, CONMED currently has an average rating of “Reduce” and a consensus price target of $41.40.

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a medical technology company that develops, manufactures and markets products used in minimally invasive surgical procedures. Its offerings support healthcare providers across a range of specialties, including general surgery, gastroenterology, pulmonology, gynecology, orthopedics and sports medicine.

The company’s products include advanced surgical devices and systems, electrosurgical equipment, smoke evacuation systems, endoscopic instruments, powered surgical tools, and orthopedic products used in arthroscopic and reconstructive procedures.